About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

VaccinesAbstracts Categorized | Comparing Types

Treatments > Vaccines > Abstracts categorized

Last update: 08/11/2016

TOPIC SEARCH: PubMed: TreatmentReview | Dendritic | Idiotype | DNA type | Heat Shock type
By site: ASCO | ASH | ClinicalTrials.govMedscape | Web
By authors: Bendandi | Levy | Timmerman

Recent Reports | Background Articles | Outcome Data

Recent Reports
bullet
2016
Cancer Vaccines: Are They the Wave of the Future? : Oncology Times http://bit.ly/2blp13O

Types and challenges described
 
bullet
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences 

The results suggest that bivalency and foreign sequences combine to increase the efficiency of chemokine-Id DNA vaccines.
bullet
Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses Despite Profound Immunosuppression  cancerres.aacrjournals.org 

Of 17 evaluable patients, five developed specific anti-vaccine antibodies, and eight developed anti-Fab T-cell responses. T-cell reactivity was independent of the cellular immune status and was idiotype specific as shown by statistical regression analysis (P = 0.0024) and epitope mapping studies. Intradermal administration of uncoupled recombinant idiotype with appropriate adjuvants may overcome profound clinical immunosuppression and induce specific immune responses.
bullet
A novel proteoliposomal vaccine induces antitumor  immunity against 
follicular lymphoma - bloodjournal.hematology 

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component
derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific. 
~ Patent information  pharmcast.com 
bullet
Custom-Made Lymphoma Vaccine Promising  - webmd.com 9-2006
Vaccine Made From Patient's Own Tumor Cells Teaches Immune System to Fight Cancer
bullet
FDA Gives Permission to Use Very Sensitive Molecular Evidence of 
Cancer in BiovaxID Pivotal Phase 3 Clinical Trial  - biz.yahoo.com
bullet
In vivo disruption of tolerogenic [tolerance producing] cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr 1;107(7):2871-8. Epub 2005 Dec 8. PMID: 16339406 | Related articles
bullet
BiovaxIDô Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial. Session Type: Poster Session 645-II 
bullet
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
Blood. 2006 Jan 15;107(2):628-36. Epub 2005 Sep 22. PMID: 16179369 | Related articles
bullet
Favrille Completes FavId Enrollment - thestreet.com
bullet
BiovaxIDô Promising for Follicular Lymphoma - cancerconsultants.com 

For patients who were in remission following PACE chemotherapy after 6 months and received BiovaxID vaccine: At a median follow-up of 9.2 years -  45% of patients remained in remission, overall survival rate is 95%. The median cancer-free survival was 8 years.
bullet
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Cancer Res. 2005 Jul 1;65(13):5958-64. PMID: 15994975 | Related articles
bullet
Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun;5(6):841-52. PMID: 15952914 | Related articles
bullet
Vaccine Therapy for Non-Hodgkin's Lymphoma: An Interview With Joseph M. Connors, MD  Hematology-Oncology 7(1), 2004. © 2004 Medscape (free login req.) 01/09/2004 
bullet
Idiotype Vaccine Following EPOCH-Rituximab Treatment in Untreated Mantle Cell Lymphoma. Wyndham H. Wilson, et al Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
 -  abstracts-on-line.com
bullet
Feasibility of idiotype vaccination was statistically compared among five different B-cell malignancies in first relapse. When based on hybridoma production techniques, idiotypic vaccination for relapsed B-cell malignancies was consistently feasible only in follicular lymphoma patients, whereas the main cause of failure in other settings was the short survival of idiotype-producing hybridomas. - haematologica.it
bullet
ASCO 2003 -  Oncophage (for indolent fNHL) in the Phase II trial, there were responses observed ...  suggesting the potential utility of the vaccine in patients with minimal residual disease. BusWire
bullet
Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma - Haematologica 2002 Apr;87(4):400-7 abstract - NIH.gov
bullet
Biovest Cancer Vaccine -- Overview of Vaccine Results - accentia.net
bullet
CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol. 2000 Dec;30(12):3591-7. - PubMed | Related abstracts
bullet
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Cancer Res. 2002 Oct 15;62(20):5845-52. PMID: 12384547 - PubMed
bullet
Vaccine Therapies for Non-Hodgkin's Lymphoma. Current Treat Options Oncol. 2002 Aug;3(4):307-15. 
PMID: 12074767 - PubMed
Return to top


Background Articles

  • APCs immunotherapy 2/4/00 - cancerpage.com 
  • Anti-idiotype vaccines for human follicular lymphoma. Leukemia. 2000 Aug;14(8):1333-9. 
    Review. PMID: 10942225 - PubMed 
  • Anti-idiotypic DNA vaccines for B-cell lymphoma therapy.
    Front Biosci. 2002 Jan 1;7:d228-34. Review. PMID: 11779689 - PubMed
  • Cancer Vaccines for Hematologic Malignancies: 
    Ivan M. Borrello, MD, Eduardo M. Sotomayor, MD - Medscape Free login req.
  • Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells," Journal of Experimental Medicine - PDF | PDF-Help Summer_2002
  • FDA Committee on vaccine technology, study design, etc.  (posted 2/7/01) -  PDF | PDF-Help
  • Heat Shock Proteins vaccine - White Paper from Antigenics
    Potential: From Basic Science Breakthroughs to Feasible Personalized Medicine
  • Identification of Relevant Cancer Antigens for Vaccine Development (2/23/01) - NEJM.ORG
  • Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood. 1997 Nov 1;90(9):3699-706. 
    PMID: 9345055  - Caspar CB, Levy S, Levy R. | Abstracts
  • Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Cancer Res. 2002 Oct 15;62(20):5845-52. PMID: 12384547 - PubMed
  • Immunotherapy Shows Promise for Non-Hodgkin's Lymphoma - Medscape May_20_2002 
    "The goal is really to delay or prevent the need for chemotherapy," said study author Dr. John Timmerman, an assistant professor of medicine at the University of California, Los Angeles.  
  • Retention of an idiotypic determinant in a human B-cell lymphoma undergoing immunoglobulin variable-region mutation. Proc Natl Acad Sci U S A. 1987 Jul;84(14):5053-7. PMID: 3496601 
    - PubMed | Abstracts
  • Vaccines:  Critical role of dendritic Cells  3/18/2000 - Medscape Free login req.
Return to top


Clinical Trial Outcomes & Review Articles

TOPIC SEARCH: PubMed | ASCO | Medscape

  • BiovaxIDô Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial. Session Type: Poster Session 645-II 
  • ASH 2003 Update: Cellular Therapies and Vaccines 
    for Hematologic Malignancies - CancerConsultants.com
  • Induction of T-cell responses by tumor antigen vaccination in mantle cell lymphoma following rituximab-based treatment - ASCO 2003
  • Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype.
    J Clin Oncol. 2004 Oct 13 PMID: 15483014 |
  • Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999 Oct;5(10):1171-7. PMID: 10502821
     | PDF | PDF-Help
  • Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002 Mar 1;99(5):1517-26. PMID: 11861263 PubMed
  • Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant. 2001;7(9):517-22. PMID: 11669219 - PubMed
  • Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) 
    in low-grade lymphoma - ASCO 2003
  • Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica. 2002 Sep;87(9):989-1001. PMID: 12217812
     - PubMed | Abstracts
  • Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Expert Rev Anticancer Ther. 2001 Jun;1(1):65-72. Review. PMID: 12113135 - PubMed
  • Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma -- 
    long-term results of a clinical trial. Blood. 1997 May 1;89(9):3129-35. PMID: 9129015 
    - Hsu FJ, Caspar ... Levy R. | PDF | PDF-Help | Abstracts 
  • Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Nat Med. 1996 Jan;2(1):52-8. PMID: 8564842; UI: 96135165. - Hsu FJ, et al.  See Related Articles
  • Vaccine Trials for the Clinician: Prospects for Tumor Antigens. Oncologist. 1997;2(5):284-299. 
    PMID: 10388061. - Osanto S.  See Related Articles
Return to top
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.